MergerLinks Daily Review
MergerLinks
Join a community of 250,000+ M&A professionals. Expand your network and discover new business opportunities.
Welcome to MergerLinks Daily Review. Sign up here to get the full round up of your daily dose of blue-chip M&A news directly to your inbox.
AstraZeneca to invest $300m in US facility for cell therapies.
ChrysCapital to raise $300m. (FS)
You can access today’s complete newsletter here.
Scroll down for more…
诺华 , a pharmaceutical company, agreed to acquire MorphoSys , a biopharma company, for €2.7bn ($2.9bn).?
“We are excited about the opportunity of bringing pelabresib, a potential next-generation treatment combined with ruxolitinib, to people living with myelofibrosis, a rare and debilitating form of blood cancer. With the planned acquisition of MorphoSys, we aim to further strengthen our leading pipeline and portfolio in oncology, adding to our capabilities and expertise. Building on our long-standing development partnership with MorphoSys, we look forward to continuing our work together to realize the full impact and value of their investigational medicines for patients with unmet needs,” Shreeram Aradhye , Novartis President and Chief Medical Officer.
Novartis is advised by 富而德律师事务所 .?MorphoSys is advised by Centerview Partners and Skadden, Arps, Slate, Meagher & Flom LLP and Affiliates .
Clean Harbors , an environmental and industrial services provider, agreed to acquire HEPACO, LLC , a premier environmental and emergency services company, for $400m.
“The acquisition of HEPACO aligns with our Vision 2027 long-term strategic plan for driving growth through a continued focus on value creation across all areas of our business. We see an excellent cultural fit with our two organizations that should help ensure the success of this acquisition. HEPACO has demonstrated a commitment to safety, environmental compliance and service excellence that matches our principles in these areas. We look forward to welcoming HEPACO’s talented team to the Clean Harbors family,” Michael Battles , Clean Harbors Co-CEO.
Clean Harbors is advised by Davis Malm . HEPACO is advised by Houlihan Lokey , Piper Sandler , Kirkland & Ellis and Moore & Van Allen PLLC .
领英推荐
ICONIQ Growth , a tech focused direct investment firm, led a $231m Series C round in NinjaOne , a unified IT management solutions provider, with participation from Frank Slootman and Amit Agarwal.
“ICONIQ Growth’s investment in NinjaOne is being used to make our customers more successful. We are quadrupling down on customer support, heavily investing in platform and product innovation to solve and automate more use cases, and ensuring the business can scale to meet our customers’ needs. We are in the decade of the endpoint, fueled by a wave of workers pushed remote and hybrid during and since the pandemic. Whether you are an MSP in charge of running and protecting other peoples’ businesses, or a CIO in charge of one, endpoints pose a significant risk and opportunity,” Sal Sferlazza , NinjaOne CEO and Founder.
AstraZeneca to invest $300m in US facility for cell therapies.
Pharmaceutical company 阿斯利康 said it will invest $300m in a facility in Rockville, Maryland, for discovery and development of cell therapies, Reuters reported.
More than 150 jobs will be created at the site in the United States to initially focus on manufacturing the cell therapies to enable clinical trials to be conducted, adding that the site may expand its focus to support other disease areas.
ChrysCapital to raise $300m. (FS)
ChrysCapital Management is looking to raise as much as $300m for a new fund that will allow the buyout firm to hang on to its minority stake in India’s main stock exchange, Bloomberg reported.
The Indian private equity company is working with a team at UBS Group for a so-called continuation fund that will give it more time and capital to hold its investment in National Stock Exchange of India.
Interested to find more? Sign up here to get full round up of your daily dose of blue-chip M&A news directly to your inbox.
You can access today’s complete newsletter here.